Short interest is the total number of shares lent out as per latest regulatory filings. Updated twice a month per FINRA reporting.

Short float is the total number of shares currently held as short positions divided by the total float as per latest regulatory filings. Updated twice a month per FINRA reporting.

Short float

Shorting

Short interest

DiaMedica Therapeutics Inc

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

DiaMedica Therapeutics reports strong Q2 performance and eyes global expansion

DiaMedica Therapeutics made significant progress in Q2 2023, achieving key milestones, strengthening financial position, and advancing product development.
While facing challenges in patient enrollment and legal matters, the company is well-positioned to capitalize on opportunities for global expansion and market growth.
Overall, DiaMedica's focus on efficient treatment delivery and commitment to innovation position them for future success in the biopharmaceutical industry.

DiaMedica reports solid Q3 results amidst strategic protocol enhancements

DiaMedica Therapeutics showcased robust financials in Q3 2023, driven by successful private placements and strategic cost management.
The appointment of Dr. Ambar Shah and protocol enhancements for ReMEDy2 reflect a commitment to innovation and clinical advancement.
However, challenges persist with patient enrollment, protocol adjustments, and legal proceedings, necessitating focused efforts to mitigate risks and drive progress.

DiaMedica Therapeutics reports robust 2023 performance and advances stroke treatment

DiaMedica Therapeutics' strong financial performance and progress in the ReMEDy2 trial highlight the company's growth potential.
Appointment of a new Chief Medical Officer and protocol revisions demonstrate a commitment to advancing clinical development efforts.
While facing challenges in site commitments and trial complexities, the company has opportunities for global expansion and market penetration.

DiaMedica reports robust Q1 earnings, eyes trial expansion opportunities

DiaMedica Therapeutics showcased strong financial performance and positive trial progress in Q1 2024.
While facing challenges such as increased operating expenses and a legal appeal, the company remains well-positioned for growth.
Opportunities lie in expanding trials, leveraging the success in China, and building a robust foundation for future drug development.

DiaMedica Therapeutics progresses on key programs amidst financial stability

DiaMedica Therapeutics is on track for a transformative 2025 with progress on key programs and enrollment enhancements.
Strategic protocol updates and financial stability bolster the company's position for future growth and clinical success.
Challenges around protocol changes and enrollment optimization require careful navigation for sustained progress.
Opportunities lie in protocol enhancements, regulatory milestones, and financial strength to drive innovation and market leadership.

DiaMedica progresses in clinical programs amidst funding challenges and optimism

DiaMedica Therapeutics reported positive advancements in clinical programs and financial sustainability despite funding challenges. The company's focus on innovation, strategic collaborations, and prudent financial planning bodes well for future growth and success. Key areas of enrollment, safety, and cost management require attention to navigate challenges and capitalize on growth opportunities effectively.

DiaMedica reports progress in medical programs amidst financial strength

DiaMedica Therapeutics made significant strides in their preeclampsia and stroke programs, supported by a strong financial position. While facing challenges in dose selection and program enrollment, the company's proactive approach and opportunities for expansion position them for future success. Engagement with key opinion leaders, strategic program expansions, and financial stability underscore DiaMedica's commitment to advancing medical solutions.

DiaMedica reports positive clinical results and strengthens team expertise

DiaMedica Therapeutics showcased strong performance in its preeclampsia and stroke programs, with positive interim results and progress in clinical trials. The addition of Dr. Julie Krop as Chief Medical Officer and the CFO's financial review highlight the company's strengthened expertise and financial position. While challenges in enrollment rates and financial management exist, DiaMedica has opportunities to capitalize on its clinical advancements and attract investors through upcoming milestones.

DiaMedica Therapeutics reports positive results and financial strength in Q3 2025

DiaMedica Therapeutics continues to show promise with DM199 across multiple indications. While facing challenges in enrollment and rising expenses, the company maintains a strong financial position. Opportunities for growth and development exist through ongoing clinical trials and operational improvements.

DiaMedica Therapeutics reports positive 2025 results, faces financial challenges

DiaMedica Therapeutics demonstrated strong performance in 2025 with promising results for DM199 in treating preeclampsia and stroke. The company's financial position remains robust, but challenges in managing expenses and cash flow persist. Despite challenges, DiaMedica Therapeutics has opportunities for growth through ongoing clinical trials and expanding the application of DM199.

DiaMedica advances promising treatments amidst financial stability and challenges

DiaMedica Therapeutics is advancing promising treatments for preeclampsia and acute ischemic stroke, with encouraging trial results. Financially stable with funds to support operations through 2027, but facing increased R&D expenses and regulatory challenges. Balancing operational challenges with growth opportunities in concurrent preeclampsia studies and global trial expansion. Overall, DiaMedica's progress in clinical trials and financial stability position the company for potential future success.